ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Demographics"

  • Abstract Number: 0724 • ACR Convergence 2024

    Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Salma Al Fazazi3, Vanesa Calvo-Rio4, Mónica Renuncio-García5, Adrián Martín-Gutiérrez6, Amparo Sánchez-López7, Claudia Poo-fernandez7, Clara Escagedo-Cagigas7, Maria Rodríguez-Vidriales1 and Ricardo Blanco-Alonso8, 1Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, 3Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 7Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
  • Abstract Number: 0733 • ACR Convergence 2024

    Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)

    Sai Shanmukha Sreeram Pannala1, fares Saliba2, Medha Rajamanuri3 and Veena Katikineni4, 1Staten Island University Hospital, Northwell Health, staten island, new york city, NY, 2Staten Island University Hospital, Staten Island, NY, 3Southern Illinois University School of Medicine, Springfield, IL, 4Providence, Victorville, CA

    Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…
  • Abstract Number: 1020 • ACR Convergence 2024

    Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis

    Elena Nikiphorou1, Alexis Ogdie2, Dan Twigg3, Emily Quiñones4, You-Li Ling5, Karim Masri6, Joseph C. Cappelleri7, Lidia Sanchez-Riera8, Megan Hughes9 and NICOLA MASSEY9, 1King's College London, London, United Kingdom, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Adelphi Real World, Manchester, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Collegeville, PA, 7Pfizer, Groton, 8Pfizer, Madrid, 9Adelphi Real World, Bollington, United Kingdom

    Background/Purpose: Structural differences exist between the healthcare systems in the United States (US) and Europe. In real-world clinical settings, we investigated whether these differences create…
  • Abstract Number: 1107 • ACR Convergence 2024

    Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

    Carine Moezinia1, Jan Nouza2, Beatrice Hornstein-Lasry2, Luai Kawar2, Asim Khan2 and Jessica Manson2, 1University College London Hospital, London, England, United Kingdom, 2University College London Hospital, London, United Kingdom

    Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
  • Abstract Number: 1251 • ACR Convergence 2024

    Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives

    Xenofon Baraliakos1, Victoria Navarro Compán2, Elena Nikiphorou3, Thao Pham4, Francesco Ciccia5, Megan Hughes6, Bruno Kranz6, Anna Jus7, Chris Watson7, Jo Lowe8 and Sofia Ramiro9, 1Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3King's College London, London, United Kingdom, 4Assistance Publique-Hôpitaux de Marseille, Marseille, France, 5Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, 6Adelphi Real World, Bollington, United Kingdom, 7Alfasigma S.p.A., Bologna, Italy, 8Axial Spondyloarthritis International Federation, London, United Kingdom, 9Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
  • Abstract Number: 1546 • ACR Convergence 2024

    Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA

    Anisha M. Patel1, Carmen Ng1, Lisa Lindsay1, Zhiyu Xia2, William F. Pendergraft III3 and Maria Dall'Era4, 1Genentech, Inc., South San Francisco, 2Genentech, Inc., Sou, 3Genentech, Inc., Chapel Hill, NC, 4UCSF, Corte Madera, CA

    Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
  • Abstract Number: 1747 • ACR Convergence 2024

    Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis

    Parmita Das1, Snehin Rajkumar2, Eric Yen3 and Ram Singh4, 1University of California Los Angeles, Saint Johns, 2UCLA David Geffen School of Medicine, Irvine, CA, 3UCLA, Los Angeles, CA, 4UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
  • Abstract Number: 1877 • ACR Convergence 2024

    Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities

    Aviraag Vijaya Prakash1, Vishwas Hosur Ravishankar2, Aishwarya Sudheer1 and Paramarajan Piranavan3, 1Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, 2St Vincents Hospital, Worcester, MA, 3University of Kentucky, Division of Rheumatology, Lexington, KY

    Background/Purpose: Rheumatoid Arthritis (RA) exhibits varied epidemiological patterns across states in the United States, influencing disability-adjusted life years (DALYs), incidence rates, prevalence, and mortality. This…
  • Abstract Number: 0139 • ACR Convergence 2024

    Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040

    CLAUDIA MENDOZA-PINTO1, IVET ETCHEGARAY MORALES2, PAMELA MUNGUIA-REALPOZO1, Socorro Méndez-Martínez3, Álvaro Montiel-Jarquín1, Roberto Berra-Romani4, Fernanda Solis-Mendoza5 and Mario García-Carrasco6, 1Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 3Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, 4Benemérita Universidad Autónoma de PueblaPueblam, Puebla, Puebla, Mexico, 5Universidad de las Américas de Puebla, Puebla, Puebla, Mexico, 6Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder related to disability and premature mortality. Nowadays, the burden of RA is needed for healthcare…
  • Abstract Number: 1879 • ACR Convergence 2024

    Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023

    Mario Bautista-Vargas1, Adrian Romero-Ocampo2, Juan José Pino Vélez3, juliana Muñoz-Bedoya4 and Diego Rosselli5, 1Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, 2Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, 3Universidad de Antioquia, Envigado, Antioquia, Colombia, 4Universidad Corpas, Bogotá, Colombia, 5Pontificia Universidad Javeriana, Bogotá, Colombia

    Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
  • Abstract Number: 0143 • ACR Convergence 2024

    Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021

    GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
  • Abstract Number: 1941 • ACR Convergence 2024

    No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders

    Nicola Jackson1, kim Nguyen2, Tien Nguyen3, Meg James3 and Avis Ware4, 1University of Cincinnati, Blue Ash, 2Trihealth Hospital, Cincinnati, 3University of Cincinnati, Cincinnati, 4University of Cincinnati, Cincinnati, OH

    Background/Purpose:  Patient no-show and cancellation rates are long-standing problems in the healthcare system, affecting patient outcomes, revenue, system efficiency, and resource utilization. At the Hoxworth…
  • Abstract Number: 0144 • ACR Convergence 2024

    More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups

    John Chen1, Tanya Selvam1, Jeanne Darbinian2, Christopher Macko1, Nirmala Ramalingam2, Joan Lo2 and Lucy Liu2, 1Kaiser Permanente Oakland Medical Center, Oakland, CA, 2Kaiser Permanente, Oakland, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a disabling, autoimmune condition affecting up to as many as 17.6 million individuals worldwide. Epidemiologic evidence in the United States…
  • Abstract Number: 2334 • ACR Convergence 2024

    Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)

    Murat Torgutalp1, Valderilio Azevedo2, Xenofon Baraliakos3, Filip Van den Bosch4, Jürgen Braun5, Alberto Cauli6, Laura Coates7, Vinod Chandran8, Torsten Diekhoff9, Floris van Gaalen10, Rodrigo Garcia Salinas11, Lianne S Gensler12, Niti Goel13, Alice Gottlieb14, Desiree van der Heijde15, Philip Helliwell16, Kay Geert Hermann17, Umut Kalyoncu18, Uta Kiltz19, Robert Lambert20, Ying Ying Leung21, Maria Llop22, Alejandra Lopez23, Miranda van Lunteren24, Ajesh Maharaj25, Walter Maksymowych26, Helena Marzo-Ortega27, Ashish J Mathew28, Philip Mease29, Peter Nash30, Mikkel Ostergaard31, Fabian Proft32, Mikhail Protopopov33, Sherry Rohekar34, RUXANDRA ELENA SCHIOTIS35, Joachim Sieper36, Enrique R. Soriano37, Lai-shan Tam38, James Wei39, Nelly Ziade40, Dafna Gladman41 and Denis Poddubnyy42, and AXIS Cohort Investigators, 1Charite Universitatsmedizin - Berlin, Berlin, Germany, 2Department of Internal Medicine, Universidade Federal of Paraná, Curitiba, Brazil, Curitiba, Brazil, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Ghent University Hospital, Ghent, Belgium, 5Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany., Herne, Germany, 6University of Cagliari, Cagliari, Italy, 7University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 8University of Toronto, Toronto, ON, Canada, 9Charite Universitatsmedizin Berlin, Berlin, Germany, 10LUMC, Leiden, Zuid-Holland, Netherlands, 11Hospital Italiano La Plata, La Plata, Argentina, 12Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 13Caduceus Biomedical Consulting, Duke University, Durham, NC, 14Department of Dermatology, Icahn School of Medicine, New York, NY, USA., New York, NY, 15Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 16Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, 17Charite Medical School, Berlin, Germany, 18Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 19Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 20University of Alberta, Edmonton, AB, Canada, 21Singapore General Hospital, Singapore, Singapore, 22Hospital Parc Tauli, Sabadell, Spain, 23Centro Dermatológico del Country, Guadalajara, Jalisco, Mexico, Guadalajara, Mexico, 24Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 25Department of Internal Medicine & Therapeutics, Faculty of Health Sciences. Walter Sisulu University, Eastern Cape, South Africa, Eastern Cape, South Africa, 26Department of Medicine, University of Alberta, Edmonton, AB, Canada; CARE Arthritis, Edmonton, AB, Canada, Edmonton, Canada, 27NIHR Leeds BRC, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, 28Christian Medical College, Vellore, Tamil Nadu, India, 29Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 30School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 31Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 32Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 33Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 34Western University, London, Ontario, Canada, London, Canada, 35SPITAL CLINIC DE BOLI INFECTIOASE CLUJ NAPOCA, Cluj-Napoca, Romania, 36Charité University Medicine Berlin, Berlin, Germany, 37Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 38The Chinese University of Hong Kong, New Territories, Hong Kong, 39Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China), 40Saint-Joseph University, Beirut, Lebanon, 41University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 42Charite-Universitatsmedizin Berlin, Berlin, Germany

    Background/Purpose: Axial involvement, affecting the sacroiliac joints (SIJ) and/or spine, is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Previous…
  • Abstract Number: 0185 • ACR Convergence 2024

    New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities

    Jonathan Katz1, Ang Yu2, Felix Elwert2, Robert Greenlee3, David Gazeley4, Ann Rosenthal5, Jenna Cormier5, Bryn Sutherland5, Shalvi Parikh6, Yiran Jiang7 and Christie Bartels8, 1University of Wisconsin Hospitals and Clinics, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3Marshfield Clinical Research Institute, Marshfield, WI, 4Medical College of Wisconsin, Wauwatosa, WI, 5Medical College of Wisconsin, Milwaukee, WI, 6Mississippi Delta Family Medicine Residency, Greenville, MS, 7Annapolis Rheumatology, Washington, DC, 8University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations.  SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology